Discover more about GASTROClear

The GASTROClear team

GASTROClear, the world’’s first molecular blood test for early detection of gastric cancer, is the result of an international collaboration involving researchers and clinicians from Singapore and Korea, led by the Singapore Gastric Cancer Consortium (SGCC).

Beginning in 2012, the collaboration involved large-scale clinical studies carried out at the National University Hospital (NUH) and Tan Tock Seng Hospital in Singapore, as well as the Yonsei Cancer Center in Korea. The Agency for Science, Technology, and Research (A*STAR), National University of Singapore (NUS), and MiRXES were also involved in the development and validation of the test, and in the subsequent regulatory approval and commercialization of GASTROClear as an in-vitro diagnostic test.

Who is MiRXES?

MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered early detection tests for disease.

In 2014, we spun off from the Agency of Science, Technology and Research (A*STAR) to commercialize our technology and develop accurate multi-cancer early detection solutions, making them readily available and accessible to people who need them.

We believe that the future of healthcare will shift from treating the sick toward preventive healthcare. Our science and innovation will continue as we are committed to changing lives by delivering preventive healthcare solutions to all.